Release Date: 2024-06-10

Use of PET/CT in Neuroendocrine Tumors

Sadiye Altun Tuzcu (Author)

Release Date: 2024-06-10

Neuroendocrine tumours (NETs) are rare tumours arising from cells with a neuroendocrine phenotype dispersed through the body and characterised by the overexpression of somatostatin receptors. Because of this unique feature, functional imaging plays a crucial role in the diagnosis and management of NETs. Ga-68 labelled somatostatin analogue PET/CT has demonstrated better performance than somatostatin receptor [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inThe Radiology of Cancer
    First Page469
    Last Page497
    DOIhttps://doi.org/10.69860/nobel.9786053359364.30
    Page Count29
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Neuroendocrine tumours (NETs) are rare tumours arising from cells with a neuroendocrine phenotype dispersed through the body and characterised by the overexpression of somatostatin receptors. Because of this unique feature, functional imaging plays a crucial role in the diagnosis and management of NETs. Ga-68 labelled somatostatin analogue PET/CT has demonstrated better performance than somatostatin receptor scintigraphy. Although different somatostatin analogues labelled with 68 Ga were available; no significant difference was found between their efficiency. Ga-68 DOTA-PET/CT has many roles on treatment including "theranostic" approach in NET patients and has a potential to be used as the first step imaging method in these patients. However, 18 F-FDG PET/CT seems to be a more appropriate imaging method as the first choice for aggressive, poorly differentiated neuroendocrine cancers. In this book chapter, we aimed to discuss radiopharmaceuticals and current imaging methods used in neuroendocrine tumors in the light of the literature.

    Sadiye Altun Tuzcu (Author)
    Associate Professor, Dicle University
    https://orcid.org/0000-0003-3326-5358
    3Associate Professor Şadiye Altun Tuzcu graduated from Dicle University Faculty of Medicine in 1996. She received her specialty training at Dicle University Faculty of Medicine, Department of Nuclear Medicine, between 2001 and 2005. After working in public hospitals and various private institutions, she worked as an academician at Dicle University, Department of Nuclear Medicine in 2019. She has many national and international research articles, posters and oral presentations, book chapters in her field.

    • Panzuto F, Partelli S, Campana D, et al. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database. Endocrine. 2024;84(1):42-47. doi:10.1007/s12020023-03649-4

    • Giri S, Sahoo J. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope. World J Gastroenterol. 2024;30(12):1670-1675. doi:10.3748/wjg.v30.i12.1670

    • Fortunati E, Bonazzi N, Zanoni L, Fanti S, Ambrosini V. Molecular imaging Theranostics of Neuroendocrine Tumors. Semin Nucl Med. 2023;53(4):539-554. doi:10.1053/j.semnuclmed.2022.12.007

    • Ullrich M, Brandt F, Löser R, Pietzsch J, Wodtke R. Comparative Saturation Binding Analysis of 64Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells. ACS Omega. 2023;8(26):2400324009. Published 2023 Jun 22. doi:10.1021/acsomega.3c02755

    • Virarkar MK, Montanarella M, Itani M, Calimano-Ramirez L, Gopireddy D, Bhosale P. PET/MRI imaging in neuroendocrine neoplasm. Abdom Radiol (NY). 2023;48(12):3585-3600. doi:10.1007/s00261-02203757-1

    • Richter S, Steenblock C, Fischer A, et al. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments. Theranostics. 2024;14(1):17-32. Published 2024 Jan 1. doi:10.7150/thno.87345

    • Nappo G, Funel N, Giudici S, et al. Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report. BMC Surg. 2020;20(1):331. Published 2020 Dec 14. doi:10.1186/s12893-020-01004-2

    • Belabed W, Mnif F, Missaoui AM, et al. Insulinoma with equivocal imaging. Endocrinol Diabetes Metab Case Rep. 2023;2023(2):23-0015. Published 2023 May 25. doi:10.1530/EDM-23-0015

    • Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P. Ga-68 DOTA-peptides and F-18 FDG PET/ CT in patients with neuroendocrine tumor: A review. Clin Imaging. 2020;67:113-116. doi:10.1016/j.clinimag.2020.05.035

    • Saponjski J, Macut D, Petrovic N, et al. Diagnostic and prognostic value of 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT in a single-center cohort of neuroendocrine tumors. Arch Med Sci. 2021;19(6):1753-1759. Published 2021 Mar 18. doi:10.5114/aoms/130996

    • Wong KK, Frey KA, Niedbala J, et al. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors. Nucl Med Commun. 2022;43(8):892-900. doi:10.1097/MNM.0000000000001592

    • Dubash S, Barwick TD, Kozlowski K, et al. Somatostatin Receptor Imaging with [18F]FET-βAGTOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study. J Nucl Med. Published online February 8, 2024. doi:10.2967/ jnumed.123.266601

    • Chen D, Yang S, Chen J, et al. Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2023;50(8):24202431. doi:10.1007/s00259-023-06200-9

    • De Rycke O, Perrier M, Ouvrard É, et al. High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d’étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network. J Nucl Med. 2023;64(11):16991705. doi:10.2967/jnumed.123.265584

    • Shen K, Yu M, Ji Y, et al. 18 F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis. Prostate. 2023;83(12):1167-1175. doi:10.1002/pros.24559

    • Haidar M, Al Mahmasani L, Chehade L, et al. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review. Nucl Med Commun. 2023;44(6):471-479. doi:10.1097/MNM.0000000000001683

    • Hu X, Li D, Wang R, Wang P, Cai J. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study. Medicine (Baltimore). 2023;102(19):e33726. doi:10.1097/MD.0000000000033726

    • Adnan A, Basu S. Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel). 2023;13(13):2154. Published 2023 Jun 24. doi:10.3390/diagnostics13132154

    • Ninatti G, Mapelli P. Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?. Eur J Nucl Med Mol Imaging. 2023;50(8):22462247. doi:10.1007/s00259-023-06275-4

    • Gallium Ga 68 Dotatate. In: Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; October 15, 2023.

    • Murphy R, Chander G, Martinez M, et al. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. BMJ Open. 2023;13(10):e075221. Published 2023 Oct 24. doi:10.1136/bmjopen-2023-075221

    • Trautwein NF, Schwenck J, Jacoby J, et al. Long-term prognostic factors for PRRT in neuroendocrine tumors. Front Med (Lausanne). 2023;10:1169970. Published 2023 Jun 9. doi:10.3389/fmed.2023.1169970

    • Boeckxstaens L, Pauwels E, Vandecaveye V, et al. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res. 2023;13(1):53. Published 2023 Jun 1. doi:10.1186/s13550-023-01003-3

    • Nogareda Seoane Z, Mallón Araújo MC, Calatayud Cubes A, et al. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT. Rev Esp Med Nucl Imagen Mol (Engl Ed). Published online April 21, 2024. doi:10.1016/j.remnie.2024.500011

    • Ha S, Kim YI, Oh JS, Yoo C, Ryoo BY, Ryu JS. Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour. EJNMMI Phys. 2024;11(1):14. Published 2024 Feb 5. doi:10.1186/s40658-02400620-8

    • WHO Classification of Tumours Editorial Board; Digestive System Tumours, WHO Classification of Tumours. 5th ed. Lyon, France: IARC Press; 2019.

    • Woltering EA, Bergsland EK, Beyer DT. Neuroendocrine Tumors of the Stomach. American Joint Committee on Cancer 2017. In: Amin MB editor. AJCC Cancer Staging Manual. Eighth Edition. Springer 2017:351-359.

    • Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(7):839-868. Published 2021 Jul 28. doi:10.6004/jnccn.2021.0032

    • Akhavanallaf A, Peterson AB, Fitzpatrick K, et al. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry. Eur J Nucl Med Mol Imaging. 2023;50(10):2984-2996. doi:10.1007/s00259-023-06252-x

    • Lindner O, Pascual TN, Mercuri M, et al. Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries. Eur J Nucl Med Mol Imaging. 2016;43(4):718-728. doi:10.1007/s00259-015-3270-8

    • Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):23232341. doi:10.1007/s00259-022-05780-2

    • Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [published correction appears in Lancet Oncol. 2019 May;20(5):e242]. Lancet Oncol. 2017;18(3):e143-e152. doi:10.1016/S1470-2045(17)30074-8

    • Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-1434.

    • Haug AR, Auernhammer CJ, Wängler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51:1349-1356.

    • Huizing DMV, Aalbersberg EA, Versleijen MWJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging 2020;20:57.

    • Xu W, Cai J, Meng T, Pang Y, Chen H. SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapan creatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2024;51(2):606-608. doi:10.1007/ s00259-023-06428-5

    • Mapelli P, Bezzi C, Muffatti F, et al. Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2023;50(9):2818-2829. doi:10.1007/s00259-023-06210-7

    • Werner RA, Lapa C, Ilhan H, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 2017;8:7039-7049.

    • Werner RA, Ilhan H, Lehner S, et al. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol 2019;21:582-590.

    • Weber M, Kessler L, Schaarschmidt B, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer 2020;20:326.

    • Liberini V, Huellner MW, Grimaldi S, et al. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:1083.

    • Veenstra EB, de Groot DJA, Brouwers AH, Walenkamp AME, Noordzij W. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms. Clin Nucl Med. 2021;46(3):195-200. doi:10.1097/RLU.0000000000003447

    • de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, et al. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clin Nucl Med. 2019;44(8):612-619. doi:10.1097/RLU.0000000000002640

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!